P1020: SELINEXOR (SEL) PLUS RUXOLITINIB (RUX) IN JAK INHIBITOR (JAKI) TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS: UPDATED RESULTS FROM XPORT-MF-034

• Haris Ali,
• Ashwin Kishtagari,
• Keri Maher,
• Sanjay Mohan,
• Josef Prchal,
• Xulong Wang,
• Kamal Chamoun,
• Srinivas Tantravahi

Affiliations

Haris Ali

1 City of Hope Comprehensive Cancer Center - Duarte, Duarte, United States

Ashwin Kishtagari

2 Vanderbilt-Ingram Cancer Center, Nashville, United States

Keri Maher

3 VCU Massey Cancer Center: Linen-Powell Resource Library, Richmond, United States

Sanjay Mohan

2 Vanderbilt-Ingram Cancer Center, Nashville, United States

Josef Prchal

4 Huntsman Cancer Institute, University of Utah, Division of Hematology and Hematologic Malignancies, Salt Lake City, United States

Xulong Wang

5 Karyopharm Therapeutics, Newton, United States

Kamal Chamoun

5 Karyopharm Therapeutics, Newton, United States

Srinivas Tantravahi

4 Huntsman Cancer Institute, University of Utah, Division of Hematology and Hematologic Malignancies, Salt Lake City, United States